Cargando…
Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research
The primary goal for any clinical trial after it receives a funding notification is to receive regulatory approval and initiate the trial for recruitment. Every trial must go through documentation and regulatory process before it can start recruiting participants and collecting data; this initial pr...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121646/ https://www.ncbi.nlm.nih.gov/pubmed/34027224 http://dx.doi.org/10.1016/j.conctc.2021.100774 |
_version_ | 1783692405292138496 |
---|---|
author | Cernik, Colin Shergina, Elena Thompson, Jeffrey Blackwell, Karen Stephens, Kyle Kimminau, Kim S. Wick, Jo Mayo, Matthew S. Gajewski, Byron He, Jianghua Mudaranthakam, Dinesh Pal |
author_facet | Cernik, Colin Shergina, Elena Thompson, Jeffrey Blackwell, Karen Stephens, Kyle Kimminau, Kim S. Wick, Jo Mayo, Matthew S. Gajewski, Byron He, Jianghua Mudaranthakam, Dinesh Pal |
author_sort | Cernik, Colin |
collection | PubMed |
description | The primary goal for any clinical trial after it receives a funding notification is to receive regulatory approval and initiate the trial for recruitment. Every trial must go through documentation and regulatory process before it can start recruiting participants and collecting data; this initial process of review and approval is known as the study start-up process (SSU). We evaluated the average time taken for studies to receive approvals. Using data from clinical trials conducted at the University of Kansas Medical Center, various times to reach the start of the study were calculated based on the dates of individual study. The results of this analysis showed that chart review studies and investigator-initiated trials had a shorter time to activation than other types of studies. Additionally, single-center studies had a shorter activation time than multi-center studies. The analysis also demonstrated that the overall processing time consistently had been reduced over time. |
format | Online Article Text |
id | pubmed-8121646 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-81216462021-05-20 Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research Cernik, Colin Shergina, Elena Thompson, Jeffrey Blackwell, Karen Stephens, Kyle Kimminau, Kim S. Wick, Jo Mayo, Matthew S. Gajewski, Byron He, Jianghua Mudaranthakam, Dinesh Pal Contemp Clin Trials Commun Article The primary goal for any clinical trial after it receives a funding notification is to receive regulatory approval and initiate the trial for recruitment. Every trial must go through documentation and regulatory process before it can start recruiting participants and collecting data; this initial process of review and approval is known as the study start-up process (SSU). We evaluated the average time taken for studies to receive approvals. Using data from clinical trials conducted at the University of Kansas Medical Center, various times to reach the start of the study were calculated based on the dates of individual study. The results of this analysis showed that chart review studies and investigator-initiated trials had a shorter time to activation than other types of studies. Additionally, single-center studies had a shorter activation time than multi-center studies. The analysis also demonstrated that the overall processing time consistently had been reduced over time. Elsevier 2021-05-04 /pmc/articles/PMC8121646/ /pubmed/34027224 http://dx.doi.org/10.1016/j.conctc.2021.100774 Text en © 2021 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Cernik, Colin Shergina, Elena Thompson, Jeffrey Blackwell, Karen Stephens, Kyle Kimminau, Kim S. Wick, Jo Mayo, Matthew S. Gajewski, Byron He, Jianghua Mudaranthakam, Dinesh Pal Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research |
title | Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research |
title_full | Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research |
title_fullStr | Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research |
title_full_unstemmed | Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research |
title_short | Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research |
title_sort | non-cancer clinical trials start-up metrics at an academic medical center: implications for advancing research |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121646/ https://www.ncbi.nlm.nih.gov/pubmed/34027224 http://dx.doi.org/10.1016/j.conctc.2021.100774 |
work_keys_str_mv | AT cernikcolin noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch AT sherginaelena noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch AT thompsonjeffrey noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch AT blackwellkaren noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch AT stephenskyle noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch AT kimminaukims noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch AT wickjo noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch AT mayomatthews noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch AT gajewskibyron noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch AT hejianghua noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch AT mudaranthakamdineshpal noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch |